JCR Pharmaceuticals Co Ltd 2024 Annual Report
The report highlights JCR's J-Brain Cargo® technology and the approval of JR-141 (Izcargo®) in Japan, presenting the achievement as a breakthrough for patients with rare diseases. It also describes more than 17 pipeline products in the lysosomal storage disorder space and development activity across global markets. Sustainability disclosures cover formal advisory, sustainability, and environmental committees, together with material issues and FY2023 indicators.
Company: JCR Pharmaceuticals Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: Annual Report
Pages: 12
Back to company
JCR Pharmaceuticals Co Ltd
Jcr Report
The report highlights JCR's J-Brain Cargo® technology and the approval of JR-141 (Izcargo®) in Japan, presenting the achievement as a breakthrough for patients with rare diseases. It also describes more than 17 pipeline products in the lysosomal storage disorder space and development activity across global markets. Sustainability disclosures cover formal advisory, sustainability, and environmental committees, together with material issues and FY2023 indicators.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Annual Report
Language
English
Pages
File Size
Standards & Assurance
No data available
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees